CCLA Investment Management lessened its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 439,732 shares of the conglomerate's stock after selling 27,873 shares during the quarter. CCLA Investment Management owned about 0.06% of Danaher worth $100,966,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the third quarter valued at $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter worth $50,000. Darwin Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth $55,000. Finally, Modus Advisors LLC acquired a new stake in shares of Danaher in the fourth quarter valued at about $56,000. 79.05% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
DHR has been the topic of several recent analyst reports. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a research note on Wednesday, October 23rd. Royal Bank of Canada decreased their target price on Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Finally, Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $286.80.
View Our Latest Stock Report on Danaher
Danaher Trading Up 0.1 %
DHR stock traded up $0.16 during trading on Wednesday, reaching $237.78. 4,128,610 shares of the stock traded hands, compared to its average volume of 3,196,188. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 52-week low of $222.53 and a 52-week high of $281.70. The firm has a market capitalization of $171.74 billion, a PE ratio of 45.38, a P/E/G ratio of 4.32 and a beta of 0.83. The business's 50 day moving average price is $235.27 and its 200-day moving average price is $253.56.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.59 billion. During the same period in the previous year, the company posted $2.02 earnings per share. Danaher's revenue was up 3.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher's dividend payout ratio is currently 20.61%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
